AT247 ultra-rapid insulin
Arecor Therapeutics
What it is
Arecor's U100 ultra-rapid insulin formulation, designed to accelerate absorption after injection or pump delivery and better match meal physiology. Early phase 1 results were reported positive and pump-delivery testing has been studied, but no phase 3 program or approval exists.
Editorial review: .
Most recent recorded citation date: 2022-01-20. Only explicit date metadata is included; an undated citation may be newer. This does not mean every claim was reviewed on that date.
Trial status, labels and access can change between reviews. How we review the evidence · How to read the evidence
Evidence behind this assessment
Key evidence notes. Study results, product eligibility and access answer different questions.
- Who was studied?
- Study populations and analysis groups vary. Product age limits alone do not describe who was studied.
- Benefit or performance
- Consistency: Only small Phase 1 clinical datasets exist; day-to-day variability in broad real-world pump use is unproven.[2]
- Important harms and treatment burden
- Read the safety discussion and original sources. A missing summary does not establish safety.
- Approval and country access
- Country-specific approval and access are not summarized in this record.Approval, trial recruitment, local supply and funding are separate. Check the cited label or access source.
- Follow-up and remaining uncertainty
- Read the full discussion and original sources for follow-up duration and study limitations.
Research status alone does not establish approval, clinical benefit or local availability. This record cites company or conference reports. Those sources may describe interim findings; their source type is shown in the source list.
Editorial score: calculation and evidence
A weighted editorial judgment on a 0–100 scale, not a probability of success or a measured treatment effect. Higher criterion scores mean more favorable assessments.
Default calculation: 74 × 20 + 68 × 25 + 62 × 15 + 50 × 20 + 50 × 10 = 5610; divide by total weight 90. Unrounded weighted result: 62.333333333333336. (Access & cost is excluded from the weighted score until commercial launch.)
AT247 is engineered for faster absorption than current rapid analogs and has reported positive early phase 1 clamp data (including a 3-day pump study), though discounted relative to approved ultra-rapids because no Phase 2/3 outpatient trial has been conducted.[2]
The formulation front-loads insulin exposure in Phase 1 clamp testing; discounted because detailed multi-week outpatient outcomes are not available.[3]
Faster early absorption shifts the action profile left in Phase 1 testing, though outpatient tail benefits remain unproven.[3]
Only small Phase 1 clinical datasets exist; day-to-day variability in broad real-world pump use is unproven.[2]
A faster profile could help exercise planning, but exercise-specific outcomes have not been reported; scored neutral.[1]
Unapproved Phase 1 pipeline candidate (0), with no active Phase 2/3 program announced.[1]
Insulins are scored relative to their role peers (see tags: rapid, ultra-rapid, basal, inhaled). A basal insulin's onset score compares it to other basals, not to mealtime insulins.
The full picture
AT247 is the U100 sibling to Arecor's concentrated AT278 program. It matters because current AID systems are held back by insulin pharmacology: algorithms can decide quickly, but injected insulin arrives slowly. AT247 is trying to shrink that lag. The limitation is development maturity: interesting early data, no late-stage T1D outcomes, and no announced phase 3 or approval timeline yet.
Coming soon
ETA · Phase 1 complete; no phase 3 or approval timeline announced
Sources
- [1]Arecor diabetes portfolio: AT247 and AT278 · Manufacturer
- [2]Arecor commences US phase I trial of AT247 delivered by insulin pump · Manufacturer · 2022-01-20
- [3]Arecor presents positive phase 1 clinical trial results for AT247 · Conference finding · 2020-06-15